Dissemin
Language
العربيّة
Deutsch
English
Español
Suomi
Français
한국어
Македонски
Português
Português Brasileiro
Русский
Svenska
Türkçe
简体中文
繁體中文
Login
Dissemin
Sarra El-Abed
Venet et al., 2023
Links
ORCID
Tools
Export citation
×
Format
BibTeX
@misc{Venet2023, author = {Venet, David and Rediti, Mattia and Maetens, Marion and Fumagalli, Debora and Brown, David N. and Majjaj, Samira and Salgado, Roberto and Pusztai, Lajos and Harbeck, Nadia and El-Abed, Sarra and Wang, Yingbo and Saura, Cristina and Gomez, Henry and Semiglazov, Vladimir Fedorovich and de Azambuja, Evandro and Huober, Jens and Nuciforo, Paolo and Di Cosimo, Serena and Piccart, Martine and Loi, Sherene and Rothé, Françoise and Sotiriou, Christos}, month = {mar}, title = {Table S1, S2, S3, S4 from Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial}, year = {2023} }
Export citation
Search in Google Scholar
Table S1, S2, S3, S4 from Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Published in 2023 by
David Venet
,
Mattia Rediti
,
Marion Maetens
,
Debora Fumagalli
,
David N. Brown
,
Samira Majjaj
,
Roberto Salgado
,
Lajos Pusztai
,
Nadia Harbeck
,
Sarra El-Abed
,
Yingbo Wang
,
Cristina Saura
,
Henry Gomez
,
Vladimir Fedorovich Semiglazov
,
Evandro de Azambuja
and
other authors.
David Venet
,
Mattia Rediti
,
Marion Maetens
,
Debora Fumagalli
,
David N. Brown
,
Samira Majjaj
,
Roberto Salgado
,
Lajos Pusztai
,
Nadia Harbeck
,
Sarra El-Abed
,
Yingbo Wang
,
Cristina Saura
,
Henry Gomez
,
Vladimir Fedorovich Semiglazov
,
Evandro de Azambuja
,
Jens Huober
,
Paolo Nuciforo
,
Serena Di Cosimo
,
Martine Piccart
,
Sherene Loi
,
Françoise Rothé
,
Christos Sotiriou
Show less
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text:
Unavailable
Preprint
: policy unknown
Upload
Postprint
: policy unknown
Upload
Published version
: policy unknown
Upload